

Encephalomyelitis Therapeutic Pipeline Market Review, H2 2016

Encephalomyelitis: Consumption, Demand, Sales, Competitor and Forecast 2016 – 2021

PUNE, INDIA, September 26, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Encephalomyelitis](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects.

Complete Report @

<https://www.wiseguyreports.com/reports/649787-encephalomyelitis-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Encephalomyelitis
- The report reviews pipeline therapeutics for Encephalomyelitis by companies and



universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Encephalomyelitis therapeutics and enlists all their major and minor projects
- The report assesses Encephalomyelitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Encephalomyelitis

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/649787-encephalomyelitis-pipeline-review-h2-2016>

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Encephalomyelitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Encephalomyelitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ <https://www.wiseguyreports.com/enquiry/649787-encephalomyelitis-pipeline-review-h2-2016>

Table of Content

Therapeutics Development 7

Pipeline Products for Encephalomyelitis - Overview 7

Pipeline Products for Encephalomyelitis - Comparative Analysis 8

Encephalomyelitis - Therapeutics under Development by Companies	9
Encephalomyelitis - Therapeutics under Investigation by Universities/Institutes	10
Encephalomyelitis - Pipeline Products Glance	11
Early Stage Products	11
Encephalomyelitis - Products under Development by Companies	12
Encephalomyelitis - Products under Investigation by Universities/Institutes	13
Encephalomyelitis - Companies Involved in Therapeutics Development	14
Bionure Farma, S.L.	14
Biovista Inc.	15
Momenta Pharmaceuticals, Inc.	16
OSE Immunotherapeutics	17
Encephalomyelitis - Therapeutics Assessment	18
Assessment by Monotherapy Products	18
Assessment by Target	19
Assessment by Mechanism of Action	21
Assessment by Route of Administration	23
Assessment by Molecule Type	24
Drug Profiles	26
Antibody for Autoimmune Disorders and Inflammation - Drug Profile	26
Product Description	26
Mechanism Of Action	26
R&D Progress	26
BN-201 - Drug Profile	27
Product Description	27
Mechanism Of Action	27
R&D Progress	27
FR-104 - Drug Profile	29
Product Description	29
Mechanism Of Action	29
R&D Progress	29
JM-4 - Drug Profile	32
Product Description	32
Mechanism Of Action	32
R&D Progress	32
PSA-20 - Drug Profile	33
Product Description	33
Mechanism Of Action	33
R&D Progress	33
Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile	34
Product Description	34
Mechanism Of Action	34
R&D Progress	34
thymulin - Drug Profile	35

Product Description 35
Mechanism Of Action 35
R&D Progress 35
WEHI-345 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Encephalomyelitis - Dormant Projects 37
Appendix 39
Methodology 39
Coverage 39
Continued...

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649787 □

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/346503356>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.